WHO Immunization Implementation Guide
0.1.0 - CI Build
WHO Immunization Implementation Guide
0.1.0 - CI Build
WHO Immunization Implementation Guide, published by World Health Organization (WHO). This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/WorldHealthOrganization/smart-immunizations and changes regularly. See the Directory of published versions
| Draft as of 2024-05-30 |
<CodeSystem xmlns="http://hl7.org/fhir">
<id value="IMMZ.D1"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>This case-insensitive code system <code>http://smart.who.int/ig/smart-immunizations/CodeSystem/IMMZ.D1</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style="white-space:nowrap">DE109<a name="IMMZ.D1-DE109"> </a></td><td>Birth dose</td><td>Indicates if the client received a dose within 24 hours of birth. Whether a birth dose is counted as part of the primary series will depend on the antigen.</td></tr><tr><td style="white-space:nowrap">DE103<a name="IMMZ.D1-DE103"> </a></td><td>Type of dose</td><td>The type of dose in a series that the client received</td></tr><tr><td style="white-space:nowrap">DE104<a name="IMMZ.D1-DE104"> </a></td><td>Primary series</td><td>Indicates that the client received the primary vaccination series of a product/antigen. This is also applicable for antigens with one dose.</td></tr><tr><td style="white-space:nowrap">DE105<a name="IMMZ.D1-DE105"> </a></td><td>Dose 0</td><td>Indicates that the client received a dose of a product/ antigen within 24 hours of birth. This dose is not a part of the primary vaccination series.</td></tr><tr><td style="white-space:nowrap">DE106<a name="IMMZ.D1-DE106"> </a></td><td>Supplementary dose</td><td>Indicates that the client received a supplementary dose of a product/antigen</td></tr><tr><td style="white-space:nowrap">DE107<a name="IMMZ.D1-DE107"> </a></td><td>Booster dose</td><td>Indicates that the client received booster dose of a product/antigen</td></tr><tr><td style="white-space:nowrap">DE8<a name="IMMZ.D1-DE8"> </a></td><td>Completed the primary vaccination series</td><td>Indicates if the client has completed the primary vaccination series of a product/antigen. If the client has not yet completed their primary series, it means they may be expected to receive more doses to complete their vaccination regimen for the respective product/antigen.</td></tr><tr><td style="white-space:nowrap">DE102<a name="IMMZ.D1-DE102"> </a></td><td>Completed the booster series</td><td>Indicates if the client has completed the booster series of a product/antigen</td></tr><tr><td style="white-space:nowrap">DE81<a name="IMMZ.D1-DE81"> </a></td><td>Date when primary vaccination series was completed</td><td>The date when the client completed the primary vaccination series (per product/antigen)</td></tr><tr><td style="white-space:nowrap">DE10<a name="IMMZ.D1-DE10"> </a></td><td>HIV status</td><td>The current human immunodeficiency virus (HIV) status of the client</td></tr><tr><td style="white-space:nowrap">DE11<a name="IMMZ.D1-DE11"> </a></td><td>HIV-positive</td><td>The client is known to be HIV positive</td></tr><tr><td style="white-space:nowrap">DE12<a name="IMMZ.D1-DE12"> </a></td><td>HIV-negative</td><td>The client is known to be HIV negative</td></tr><tr><td style="white-space:nowrap">DE13<a name="IMMZ.D1-DE13"> </a></td><td>Unknown</td><td>The client's HIV status is unknown</td></tr><tr><td style="white-space:nowrap">DE15<a name="IMMZ.D1-DE15"> </a></td><td>Preterm birth</td><td>The infant was preterm; the mother gave birth to the infant when gestational age was less than 37 weeks</td></tr><tr><td style="white-space:nowrap">DE16<a name="IMMZ.D1-DE16"> </a></td><td>Immunocompromised</td><td>The client is known to be immunocompromised. This means the client has a weakened immune system and having a reduced ability to fight infections and other diseases</td></tr><tr><td style="white-space:nowrap">DE17<a name="IMMZ.D1-DE17"> </a></td><td>Currently on ART</td><td>The client is currently receiving antiretroviral therapy (ART)</td></tr><tr><td style="white-space:nowrap">DE84<a name="IMMZ.D1-DE84"> </a></td><td>Type of TB infection test performed</td><td>The type of TB infection test performed</td></tr><tr><td style="white-space:nowrap">DE85<a name="IMMZ.D1-DE85"> </a></td><td>IGRA</td><td>Interferon-gamma release assay (IGRA)</td></tr><tr><td style="white-space:nowrap">DE86<a name="IMMZ.D1-DE86"> </a></td><td>TST</td><td>Tuberculin skin test (TST)</td></tr><tr><td style="white-space:nowrap">DE87<a name="IMMZ.D1-DE87"> </a></td><td>TB infection test result</td><td>Records the result of the TB infection test</td></tr><tr><td style="white-space:nowrap">DE88<a name="IMMZ.D1-DE88"> </a></td><td>Positive</td><td>Test result was positive</td></tr><tr><td style="white-space:nowrap">DE89<a name="IMMZ.D1-DE89"> </a></td><td>Negative</td><td>Test result was negative</td></tr><tr><td style="white-space:nowrap">DE93<a name="IMMZ.D1-DE93"> </a></td><td>Immunologically stable</td><td>The client is living with HIV and is immunologically stable with CD4 count or percentage above a minimum as defined in the HIV guidelines</td></tr><tr><td style="white-space:nowrap">DE94<a name="IMMZ.D1-DE94"> </a></td><td>Clinically well</td><td>The client is living with HIV and is clinically well, as defined in HIV guidelines and WHO clinical staging</td></tr><tr><td style="white-space:nowrap">DE29<a name="IMMZ.D1-DE29"> </a></td><td>Birth weight in grams</td><td>Represents the client's birth weight value measures in grams</td></tr><tr><td style="white-space:nowrap">DE35<a name="IMMZ.D1-DE35"> </a></td><td>Type of polio dose</td><td>The type of the polio vaccine dose administered to the client</td></tr><tr><td style="white-space:nowrap">DE36<a name="IMMZ.D1-DE36"> </a></td><td>IPV</td><td>Inactivated poliovirus vaccine (IPV)</td></tr><tr><td style="white-space:nowrap">DE37<a name="IMMZ.D1-DE37"> </a></td><td>bOPV</td><td>Bivalent oral poliovirus vaccine (bOPV)</td></tr><tr><td style="white-space:nowrap">DE92<a name="IMMZ.D1-DE92"> </a></td><td>Severely immunosuppressed</td><td>The client is known to be severely immunosuppressed</td></tr><tr><td style="white-space:nowrap">DE49<a name="IMMZ.D1-DE49"> </a></td><td>ART start date</td><td>The date on which the client started or restarted antiretroviral therapy (ART)</td></tr><tr><td style="white-space:nowrap">DE96<a name="IMMZ.D1-DE96"> </a></td><td>High risk of pneumococcal infection</td><td>The client is at high risk for pneumococcal infection because of underlying medical conditions (i.e. HIV infection or sickle-cell disease)</td></tr><tr><td style="white-space:nowrap">DE52<a name="IMMZ.D1-DE52"> </a></td><td>Type of JE dose</td><td>The type of Japanese encephalitis (JE) vaccine dose administered to the client</td></tr><tr><td style="white-space:nowrap">DE53<a name="IMMZ.D1-DE53"> </a></td><td>Inactivated Vero cell-derived vaccine</td><td>Inactivated Vero cell-derived Japanese encephalitis (JE) vaccine type</td></tr><tr><td style="white-space:nowrap">DE54<a name="IMMZ.D1-DE54"> </a></td><td>Live attenuated vaccine</td><td>Live attenuated Japanese encephalitis (JE) vaccine type</td></tr><tr><td style="white-space:nowrap">DE55<a name="IMMZ.D1-DE55"> </a></td><td>Live recombinant vaccine</td><td>Live recombinant Japanese encephalitis (JE) vaccine type</td></tr><tr><td style="white-space:nowrap">DE56<a name="IMMZ.D1-DE56"> </a></td><td>Type of TBE dose</td><td>The type of tick-borne encephalitis (TBE) vaccine dose administered</td></tr><tr><td style="white-space:nowrap">DE57<a name="IMMZ.D1-DE57"> </a></td><td>FSME-Immun</td><td>FSME-Immun vaccine product, which is an inactivated whole-virus vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style="white-space:nowrap">DE58<a name="IMMZ.D1-DE58"> </a></td><td>Encepur</td><td>Encepur vaccine product, which is an inactivated viral vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style="white-space:nowrap">DE59<a name="IMMZ.D1-DE59"> </a></td><td>TBE-Moscow</td><td>TBE-Moscow vaccine product, which is a vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style="white-space:nowrap">DE60<a name="IMMZ.D1-DE60"> </a></td><td>EnceVir</td><td>EnceVir vaccine product, which is a vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style="white-space:nowrap">DE61<a name="IMMZ.D1-DE61"> </a></td><td>Type of typhoid dose</td><td>The type of typhoid vaccine dose administered to the client</td></tr><tr><td style="white-space:nowrap">DE62<a name="IMMZ.D1-DE62"> </a></td><td>Typbar-TCV</td><td>Typbar-TCV vaccine</td></tr><tr><td style="white-space:nowrap">DE63<a name="IMMZ.D1-DE63"> </a></td><td>ViPS</td><td>Vi polysaccharide (ViPS) vaccine</td></tr><tr><td style="white-space:nowrap">DE64<a name="IMMZ.D1-DE64"> </a></td><td>Ty21a</td><td>Ty21a vaccine</td></tr><tr><td style="white-space:nowrap">DE65<a name="IMMZ.D1-DE65"> </a></td><td>Type of cholera dose</td><td>The type of cholera vaccine dose administered to the client</td></tr><tr><td style="white-space:nowrap">DE66<a name="IMMZ.D1-DE66"> </a></td><td>WC vaccine</td><td>Killed whole cell (WC) only cholera vaccine</td></tr><tr><td style="white-space:nowrap">DE67<a name="IMMZ.D1-DE67"> </a></td><td>WC-rBS vaccine</td><td>Vaccine contains a mixture of the recombinant B subunit (rBS) of cholera toxin plus killed whole cell (WC)</td></tr><tr><td style="white-space:nowrap">DE68<a name="IMMZ.D1-DE68"> </a></td><td>Type of meningococcal dose</td><td>The type of meningococcal vaccine dose administered to the client</td></tr><tr><td style="white-space:nowrap">DE69<a name="IMMZ.D1-DE69"> </a></td><td>MenA conjugate vaccine (5µg)</td><td>Monovalent serogroup A (MenA) conjugate vaccine (5µg) vaccine</td></tr><tr><td style="white-space:nowrap">DE70<a name="IMMZ.D1-DE70"> </a></td><td>Monovalent MenC conjugate</td><td>Monovalent MenC conjugate vaccine</td></tr><tr><td style="white-space:nowrap">DE71<a name="IMMZ.D1-DE71"> </a></td><td>Quadrivalent conjugate</td><td>Quadrivalent conjugate (A,C,W135,Y-D and A,C,W135,Y-CRM) vaccines</td></tr><tr><td style="white-space:nowrap">DE97<a name="IMMZ.D1-DE97"> </a></td><td>Polysaccharide vaccine</td><td>Polysaccharide vaccines not including polysaccharide-protein conjugate vaccines</td></tr><tr><td style="white-space:nowrap">DE72<a name="IMMZ.D1-DE72"> </a></td><td>Age in months when client received first meningococcal dose</td><td>The age in months when client received their first meningococcal dose</td></tr><tr><td style="white-space:nowrap">DE73<a name="IMMZ.D1-DE73"> </a></td><td>Type of hepatitis A dose</td><td>The type of hepatitis A vaccine dose administered to the client</td></tr><tr><td style="white-space:nowrap">DE74<a name="IMMZ.D1-DE74"> </a></td><td>Live attenuated hepatitis A vaccine</td><td>Live attenuated hepatitis A vaccine</td></tr><tr><td style="white-space:nowrap">DE75<a name="IMMZ.D1-DE75"> </a></td><td>Inactivated hepatitis A vaccine</td><td>Inactivated hepatitis A vaccine</td></tr><tr><td style="white-space:nowrap">DE99<a name="IMMZ.D1-DE99"> </a></td><td>Type of hepatitis B dose</td><td>The type of hepatitis B vaccine dose administered to the client</td></tr><tr><td style="white-space:nowrap">DE100<a name="IMMZ.D1-DE100"> </a></td><td>Hepatitis B monovalent vaccine</td><td>Hepatitis B monovalent vaccine</td></tr><tr><td style="white-space:nowrap">DE101<a name="IMMZ.D1-DE101"> </a></td><td>Hepatitis B combination vaccine</td><td>Hepatitis B combination vaccine</td></tr><tr><td style="white-space:nowrap">DE76<a name="IMMZ.D1-DE76"> </a></td><td>VNA level</td><td>Vaccine-induced neutralizing (VNA) antibody level. It is a measured as a serum antibody concentration amount observed from the result of the concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEV)</td></tr><tr><td style="white-space:nowrap">DE98<a name="IMMZ.D1-DE98"> </a></td><td>Risk of occupational exposure to rabies virus</td><td>Professional at risk of occupational exposure to rabies virus, particularly animal health-care workers. Also considered for medical professionals who regularly provide care to persons with rabies.</td></tr><tr><td style="white-space:nowrap">DE77<a name="IMMZ.D1-DE77"> </a></td><td>Dengue serostatus</td><td>Indicates the result of a serological test determining whether the client has antibodies against the dengue virus</td></tr><tr><td style="white-space:nowrap">DE110<a name="IMMZ.D1-DE110"> </a></td><td>Positive</td><td>The client has detectable antibodies against the dengue virus, suggesting past exposure or vaccination</td></tr><tr><td style="white-space:nowrap">DE111<a name="IMMZ.D1-DE111"> </a></td><td>Negative</td><td>The client does not have detectable antibodies, indicating no previous exposure or vaccination against the dengue virus</td></tr><tr><td style="white-space:nowrap">DE112<a name="IMMZ.D1-DE112"> </a></td><td>Unknown</td><td>The client's dengue serostatus is unknown</td></tr></table></div>
</text>
<url
value="http://smart.who.int/ig/smart-immunizations/CodeSystem/IMMZ.D1"/>
<version value="0.1.0"/>
<name value="IMMZ_D1"/>
<title value="IMMZ.D1 CodeSystem for Data Elements"/>
<status value="draft"/>
<experimental value="false"/>
<date value="2024-05-30T21:26:16+00:00"/>
<publisher value="World Health Organization (WHO)"/>
<contact>
<name value="World Health Organization (WHO)"/>
<telecom>
<system value="url"/>
<value value="https://www.who.int"/>
</telecom>
</contact>
<description value="CodeSystem for IMMZ.D1 Data Elements"/>
<jurisdiction>
<coding>
<system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
<code value="001"/>
</coding>
</jurisdiction>
<caseSensitive value="false"/>
<content value="complete"/>
<count value="65"/>
<concept>
<code value="DE109"/>
<display value="Birth dose"/>
<definition
value="Indicates if the client received a dose within 24 hours of birth. Whether a birth dose is counted as part of the primary series will depend on the antigen."/>
</concept>
<concept>
<code value="DE103"/>
<display value="Type of dose"/>
<definition
value="The type of dose in a series that the client received"/>
</concept>
<concept>
<code value="DE104"/>
<display value="Primary series"/>
<definition
value="Indicates that the client received the primary vaccination series of a product/antigen. This is also applicable for antigens with one dose."/>
</concept>
<concept>
<code value="DE105"/>
<display value="Dose 0"/>
<definition
value="Indicates that the client received a dose of a product/ antigen within 24 hours of birth. This dose is not a part of the primary vaccination series."/>
</concept>
<concept>
<code value="DE106"/>
<display value="Supplementary dose"/>
<definition
value="Indicates that the client received a supplementary dose of a product/antigen"/>
</concept>
<concept>
<code value="DE107"/>
<display value="Booster dose"/>
<definition
value="Indicates that the client received booster dose of a product/antigen"/>
</concept>
<concept>
<code value="DE8"/>
<display value="Completed the primary vaccination series"/>
<definition
value="Indicates if the client has completed the primary vaccination series of a product/antigen. If the client has not yet completed their primary series, it means they may be expected to receive more doses to complete their vaccination regimen for the respective product/antigen."/>
</concept>
<concept>
<code value="DE102"/>
<display value="Completed the booster series"/>
<definition
value="Indicates if the client has completed the booster series of a product/antigen"/>
</concept>
<concept>
<code value="DE81"/>
<display value="Date when primary vaccination series was completed"/>
<definition
value="The date when the client completed the primary vaccination series (per product/antigen)"/>
</concept>
<concept>
<code value="DE10"/>
<display value="HIV status"/>
<definition
value="The current human immunodeficiency virus (HIV) status of the client"/>
</concept>
<concept>
<code value="DE11"/>
<display value="HIV-positive"/>
<definition value="The client is known to be HIV positive"/>
</concept>
<concept>
<code value="DE12"/>
<display value="HIV-negative"/>
<definition value="The client is known to be HIV negative"/>
</concept>
<concept>
<code value="DE13"/>
<display value="Unknown"/>
<definition value="The client's HIV status is unknown"/>
</concept>
<concept>
<code value="DE15"/>
<display value="Preterm birth"/>
<definition
value="The infant was preterm; the mother gave birth to the infant when gestational age was less than 37 weeks"/>
</concept>
<concept>
<code value="DE16"/>
<display value="Immunocompromised"/>
<definition
value="The client is known to be immunocompromised. This means the client has a weakened immune system and having a reduced ability to fight infections and other diseases"/>
</concept>
<concept>
<code value="DE17"/>
<display value="Currently on ART"/>
<definition
value="The client is currently receiving antiretroviral therapy (ART)"/>
</concept>
<concept>
<code value="DE84"/>
<display value="Type of TB infection test performed"/>
<definition value="The type of TB infection test performed"/>
</concept>
<concept>
<code value="DE85"/>
<display value="IGRA"/>
<definition value="Interferon-gamma release assay (IGRA)"/>
</concept>
<concept>
<code value="DE86"/>
<display value="TST"/>
<definition value="Tuberculin skin test (TST)"/>
</concept>
<concept>
<code value="DE87"/>
<display value="TB infection test result"/>
<definition value="Records the result of the TB infection test"/>
</concept>
<concept>
<code value="DE88"/>
<display value="Positive"/>
<definition value="Test result was positive"/>
</concept>
<concept>
<code value="DE89"/>
<display value="Negative"/>
<definition value="Test result was negative"/>
</concept>
<concept>
<code value="DE93"/>
<display value="Immunologically stable"/>
<definition
value="The client is living with HIV and is immunologically stable with CD4 count or percentage above a minimum as defined in the HIV guidelines"/>
</concept>
<concept>
<code value="DE94"/>
<display value="Clinically well"/>
<definition
value="The client is living with HIV and is clinically well, as defined in HIV guidelines and WHO clinical staging"/>
</concept>
<concept>
<code value="DE29"/>
<display value="Birth weight in grams"/>
<definition
value="Represents the client's birth weight value measures in grams"/>
</concept>
<concept>
<code value="DE35"/>
<display value="Type of polio dose"/>
<definition
value="The type of the polio vaccine dose administered to the client"/>
</concept>
<concept>
<code value="DE36"/>
<display value="IPV"/>
<definition value="Inactivated poliovirus vaccine (IPV)"/>
</concept>
<concept>
<code value="DE37"/>
<display value="bOPV"/>
<definition value="Bivalent oral poliovirus vaccine (bOPV)"/>
</concept>
<concept>
<code value="DE92"/>
<display value="Severely immunosuppressed"/>
<definition value="The client is known to be severely immunosuppressed"/>
</concept>
<concept>
<code value="DE49"/>
<display value="ART start date"/>
<definition
value="The date on which the client started or restarted antiretroviral therapy (ART)"/>
</concept>
<concept>
<code value="DE96"/>
<display value="High risk of pneumococcal infection"/>
<definition
value="The client is at high risk for pneumococcal infection because of underlying medical conditions (i.e. HIV infection or sickle-cell disease)"/>
</concept>
<concept>
<code value="DE52"/>
<display value="Type of JE dose"/>
<definition
value="The type of Japanese encephalitis (JE) vaccine dose administered to the client"/>
</concept>
<concept>
<code value="DE53"/>
<display value="Inactivated Vero cell-derived vaccine"/>
<definition
value="Inactivated Vero cell-derived Japanese encephalitis (JE) vaccine type"/>
</concept>
<concept>
<code value="DE54"/>
<display value="Live attenuated vaccine"/>
<definition
value="Live attenuated Japanese encephalitis (JE) vaccine type"/>
</concept>
<concept>
<code value="DE55"/>
<display value="Live recombinant vaccine"/>
<definition
value="Live recombinant Japanese encephalitis (JE) vaccine type"/>
</concept>
<concept>
<code value="DE56"/>
<display value="Type of TBE dose"/>
<definition
value="The type of tick-borne encephalitis (TBE) vaccine dose administered"/>
</concept>
<concept>
<code value="DE57"/>
<display value="FSME-Immun"/>
<definition
value="FSME-Immun vaccine product, which is an inactivated whole-virus vaccine for tick-borne encephalitis (TBE)"/>
</concept>
<concept>
<code value="DE58"/>
<display value="Encepur"/>
<definition
value="Encepur vaccine product, which is an inactivated viral vaccine for tick-borne encephalitis (TBE)"/>
</concept>
<concept>
<code value="DE59"/>
<display value="TBE-Moscow"/>
<definition
value="TBE-Moscow vaccine product, which is a vaccine for tick-borne encephalitis (TBE)"/>
</concept>
<concept>
<code value="DE60"/>
<display value="EnceVir"/>
<definition
value="EnceVir vaccine product, which is a vaccine for tick-borne encephalitis (TBE)"/>
</concept>
<concept>
<code value="DE61"/>
<display value="Type of typhoid dose"/>
<definition
value="The type of typhoid vaccine dose administered to the client"/>
</concept>
<concept>
<code value="DE62"/>
<display value="Typbar-TCV"/>
<definition value="Typbar-TCV vaccine"/>
</concept>
<concept>
<code value="DE63"/>
<display value="ViPS"/>
<definition value="Vi polysaccharide (ViPS) vaccine"/>
</concept>
<concept>
<code value="DE64"/>
<display value="Ty21a"/>
<definition value="Ty21a vaccine"/>
</concept>
<concept>
<code value="DE65"/>
<display value="Type of cholera dose"/>
<definition
value="The type of cholera vaccine dose administered to the client"/>
</concept>
<concept>
<code value="DE66"/>
<display value="WC vaccine"/>
<definition value="Killed whole cell (WC) only cholera vaccine"/>
</concept>
<concept>
<code value="DE67"/>
<display value="WC-rBS vaccine"/>
<definition
value="Vaccine contains a mixture of the recombinant B subunit (rBS) of cholera toxin plus killed whole cell (WC)"/>
</concept>
<concept>
<code value="DE68"/>
<display value="Type of meningococcal dose"/>
<definition
value="The type of meningococcal vaccine dose administered to the client"/>
</concept>
<concept>
<code value="DE69"/>
<display value="MenA conjugate vaccine (5µg)"/>
<definition
value="Monovalent serogroup A (MenA) conjugate vaccine (5µg) vaccine"/>
</concept>
<concept>
<code value="DE70"/>
<display value="Monovalent MenC conjugate"/>
<definition value="Monovalent MenC conjugate vaccine"/>
</concept>
<concept>
<code value="DE71"/>
<display value="Quadrivalent conjugate"/>
<definition
value="Quadrivalent conjugate (A,C,W135,Y-D and A,C,W135,Y-CRM) vaccines"/>
</concept>
<concept>
<code value="DE97"/>
<display value="Polysaccharide vaccine"/>
<definition
value="Polysaccharide vaccines not including polysaccharide-protein conjugate vaccines"/>
</concept>
<concept>
<code value="DE72"/>
<display
value="Age in months when client received first meningococcal dose"/>
<definition
value="The age in months when client received their first meningococcal dose"/>
</concept>
<concept>
<code value="DE73"/>
<display value="Type of hepatitis A dose"/>
<definition
value="The type of hepatitis A vaccine dose administered to the client"/>
</concept>
<concept>
<code value="DE74"/>
<display value="Live attenuated hepatitis A vaccine"/>
<definition value="Live attenuated hepatitis A vaccine"/>
</concept>
<concept>
<code value="DE75"/>
<display value="Inactivated hepatitis A vaccine"/>
<definition value="Inactivated hepatitis A vaccine"/>
</concept>
<concept>
<code value="DE99"/>
<display value="Type of hepatitis B dose"/>
<definition
value="The type of hepatitis B vaccine dose administered to the client"/>
</concept>
<concept>
<code value="DE100"/>
<display value="Hepatitis B monovalent vaccine"/>
<definition value="Hepatitis B monovalent vaccine"/>
</concept>
<concept>
<code value="DE101"/>
<display value="Hepatitis B combination vaccine"/>
<definition value="Hepatitis B combination vaccine"/>
</concept>
<concept>
<code value="DE76"/>
<display value="VNA level"/>
<definition
value="Vaccine-induced neutralizing (VNA) antibody level. It is a measured as a serum antibody concentration amount observed from the result of the concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEV)"/>
</concept>
<concept>
<code value="DE98"/>
<display value="Risk of occupational exposure to rabies virus"/>
<definition
value="Professional at risk of occupational exposure to rabies virus, particularly animal health-care workers. Also considered for medical professionals who regularly provide care to persons with rabies."/>
</concept>
<concept>
<code value="DE77"/>
<display value="Dengue serostatus"/>
<definition
value="Indicates the result of a serological test determining whether the client has antibodies against the dengue virus"/>
</concept>
<concept>
<code value="DE110"/>
<display value="Positive"/>
<definition
value="The client has detectable antibodies against the dengue virus, suggesting past exposure or vaccination"/>
</concept>
<concept>
<code value="DE111"/>
<display value="Negative"/>
<definition
value="The client does not have detectable antibodies, indicating no previous exposure or vaccination against the dengue virus"/>
</concept>
<concept>
<code value="DE112"/>
<display value="Unknown"/>
<definition value="The client's dengue serostatus is unknown"/>
</concept>
</CodeSystem>